शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
EIMCOELECONSEEimco Elecon (India) Limited· Industrial ManufacturingHighNeutral
Announced Thu, 9 Oct, 2025 · 14:04 IST

September quarter revenue and profit fall sharply; new defence and pharma objects proposed

EIMCOELECO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-12.6%Reaction day
₹2301.00
prior close
₹2197.70
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.2%-12.9% vs market
Industrial Products peers, median of 116sector-0.4%-12.3% vs sector

On the reaction day the stock moved 12.9 pts less than Nifty Microcap 250 and 12.3 pts less than its Industrial Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-6.5
10m
-7.7
15m
-8.4
30m
-7.1
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-12.6+0.2-12.9-0.4-12.3
Next day
-15.2+0.9-16.1-0.0-15.1
2d
-16.8+0.4-17.2-1.1-15.7
3d
-18.9-0.8-18.2-2.2-16.7
4d
-17.8+0.2-18.0-1.4-16.4
5d
-20.7+0.7-21.4-1.3-19.4
1w
-21.2+1.2-22.4-1.3-20.0
15d
-18.8+2.0-20.8-1.1-17.7
1m
-26.2+0.6-26.9-3.5-22.7
2m
-30.1-4.2-25.9-10.7-19.3
3m
-28.9-6.1-22.8-14.4-14.5
UpDownMarket · Nifty Microcap 250Sector · Industrial Products peers, median of 116Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

For the September 2025 quarter, revenue from operations was Rs 3,323.64 lakh versus Rs 6,662.69 lakh a year ago, and net profit was Rs 535.12 lakh versus Rs 1,306.15 lakh. EPS was Rs 9.28. For the half year, revenue was Rs 10,080.63 lakh and profit Rs 1,983.38 lakh. The auditor review was unmodified. The board also proposed wider business objects.

Likely market impact

Weaker sales and profit are likely to weigh on the stock, but proposed defence and pharma business lines offer long-term growth options.